Clinical Trial Update: Multihance Versus Magnevist in Breast MRI [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MRI contrast agents Multihance and Magnevist in breast imaging has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• MULTIHANCE (Gadobenate dimeglumine)
• Magnevist (gadopentetate dimeglumine)

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED